Meet Sotirios Stergiopoulos, MD, MBEE, FACP: President, CEO, and Founder of A2A Pharma

Accomplished Physician Executive, Leading Medical Innovator, and Oncology Thought Leader

(YourDigitalWall Editorial):- New York City, New York Jun 18, 2024 ( – Dr. Sotirios Stergiopoulos, a distinguished figure in the medical field with an impressive academic background and vast experience in leading pharmaceutical companies, has embarked on a groundbreaking journey with the launch of A2A Pharma. 

The mission of A2A Pharma is to utilize cutting-edge computational systems, including Artificial Intelligence (A.I.), to expedite the development of innovative drug solutions for devastating life-threatening illnesses such as cancer, bacterial infections, and muscular dystrophy.

Dr. Stergiopoulos’ professional journey has been marked by a commitment to excellence and a relentless pursuit of advancements in medicine. He holds a Degree from Avicina Medical Academy and specializes in internal medicine and cancer genetics through training at esteemed institutions like the National Institutes of Health (NIH), Albert Einstein College of Medicine, and Harvard Medical School. He is also equipped with a Master of Biotechnology Enterprise and Entrepreneurship (MBEE) from Johns Hopkins University, further enhancing his ability to drive innovation and foster a culture of excellence within the medical community. 

In his illustrious career, Dr. Stergiopoulos has held key positions such as Chief Medical Officer, Senior Vice President, and Head of Global Medical Affairs at Ipsen, as well as Vice President and Head of Global Medical Affairs Oncology for Baxalta Inc. and Shire, where he played integral roles in medical affairs and clinical development. His previous roles at renowned pharmaceutical companies such as Bayer, Novartis, and Celgene, where he made significant contributions to medical advancements, have further solidified his reputation as a visionary leader in the industry.

A dedicated member of various prestigious medical associations, including the European Society of Translational Medicine (expert panel member of medical affairs), the American Association of Cancer Research, and the American Society of Clinical Oncology, Dr. Stergiopoulos is committed to driving impactful change in the medical field. His role as a Fellow of the American College of Physicians (committee member of the New York-Queens District), the New York Academy of Medicine, and the Royal Society of Medicine (UK) underscores his unwavering dedication to advancing healthcare practices and improving patient care. 

With the launch of A2A Pharma, Dr. Stergiopoulos is poised to lead a new era of innovation and discovery in drug development, bringing hope to millions of individuals battling life-threatening diseases.

Learn More about Dr. Sotirios Stergiopoulos:
Through his findatopdoc profile, or through A2A Pharma,


FindaTopDoc is a digital health information company that helps connect patients with local physicians and specialists who accept your insurance. Our goal is to help guide you on your journey towards optimal health by providing you with the know-how to make informed decisions for you and your family.

Media Contact

Your Health Contact


Your Health Contact
Source :Sotirios Stergiopoulos, MD, MBEE, FACP

This article was originally published by IssueWire. Read the original article here.


Next Post

Philip Paty, MD, FACS, Dual Board Certified General and Vascular Surgeon in the Capital Region

Wed Jun 19 , 2024
Bringing Decades of Experience and a Commitment to Excellence in Vascular Surgery (YourDigitalWall Editorial):- New York City, New York Jun 18, 2024 ( – Dr. Philip Paty, a highly esteemed general and vascular surgeon, serves as the Medical Director of the Non-Invasive Lab at Vascular Health Partners. With a strong presence at […]

You May Like